LeonaBio, Inc. (NASDAQ:LONA) — Market Cap & Net Worth
Market Cap & Net Worth: LeonaBio, Inc. (LONA)
LeonaBio, Inc. (NASDAQ:LONA) has a market capitalization of $66.32 Million ($66.32 Million) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #20723 globally and #4628 in its home market, demonstrating a -2.49% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying LeonaBio, Inc.'s stock price $7.06 by its total outstanding shares 9393514 (9.39 Million). Review how much debt does LeonaBio, Inc. carry to assess the company's total debt and financial obligations.
LeonaBio, Inc. Market Cap History: 2026 to 2026
LeonaBio, Inc.'s market capitalization history from 2026 to 2026. Data shows growth from $66.32 Million to $66.32 Million (0.00% CAGR).
LeonaBio, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how LeonaBio, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of LONA by Market Capitalization
Companies near LeonaBio, Inc. in the global market cap rankings as of August 3, 2026.
Key companies related to LeonaBio, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
LeonaBio, Inc. Historical Marketcap From 2026 to 2026
Between 2026 and today, LeonaBio, Inc.'s market cap moved from $66.32 Million to $ 66.32 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $66.32 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of LeonaBio, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $66.32 Million USD |
| MoneyControl | $66.32 Million USD |
| MarketWatch | $66.32 Million USD |
| marketcap.company | $66.32 Million USD |
| Reuters | $66.32 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About LeonaBio, Inc.
LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment o… Read more